3,762 reports of this reaction
1.5% of all RISPERIDONE reports
#12 most reported adverse reaction
GALACTORRHOEA is the #12 most commonly reported adverse reaction for RISPERIDONE, manufactured by Janssen Pharmaceuticals, Inc.. There are 3,762 FDA adverse event reports linking RISPERIDONE to GALACTORRHOEA. This represents approximately 1.5% of all 254,329 adverse event reports for this drug.
RISPERIDONE has an overall safety score of 85 out of 100. Patients taking RISPERIDONE who experience galactorrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GALACTORRHOEA is a less commonly reported adverse event for RISPERIDONE, but still significant enough to appear in the safety profile.
In addition to galactorrhoea, the following adverse reactions have been reported for RISPERIDONE:
The following drugs have also been linked to galactorrhoea in FDA adverse event reports:
GALACTORRHOEA has been reported as an adverse event in 3,762 FDA reports for RISPERIDONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GALACTORRHOEA accounts for approximately 1.5% of all adverse event reports for RISPERIDONE, making it a notable side effect.
If you experience galactorrhoea while taking RISPERIDONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.